Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): PNT001

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PNT001

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Advanced Technology International

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding June 17, 2021

            Details:

            Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease.